|
| 36845707 | The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study. | Front Oncol | 2023 |
| 37415654 | Current Challenges and Perspectives in Breast Cancer in Elderly Women: The Senologic International Society (SIS) Survey. | | 2023 |
| 34816585 | The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. | Mol Oncol | 2022 |
| 36268941 | GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. | Future Oncol | 2022 |
| 35855198 | The Senologic International Society Survey on Ductal Carcinoma : Present and Future. | | 2022 |
| 35110416 | Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. | Clin Cancer Res | 2022 |
| 33916671 | Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of Pt and Pt Radionuclides in Auger Electron Therapy. | Molecules | 2021 |
| 33539215 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. | Journal of Clinical Oncology | 2021 |
| 33870120 | Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey. | | 2021 |
| 31146717 | Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. | BMC Cancer | 2019 |
| 30520947 | Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. | JAMA Oncol | 2019 |
| 31234810 | Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. | BMC Cancer | 2019 |
| 31318460 | Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. | Cancer | 2019 |
| 28183321 | Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. | Breast Cancer Research | 2017 |
| 28056202 | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | Journal of Clinical Oncology | 2017 |
| 27501767 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. | Lancet Oncology, The | 2016 |
| 27179402 | 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. | Lancet Oncology, The | 2016 |
| 26940688 | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. | Ann Oncol | 2016 |
| 27573653 | HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. | J Clin Oncol | 2016 |
| 26387142 | Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. | Ann Oncol | 2015 |
| 25747197 | Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. | Breast | 2015 |
| 25649019 | PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. | Clin Cancer Res | 2015 |
| 24029456 | Delays in diagnosis and treatment of breast cancer: a multinational analysis. | European Journal of Public Health | 2014 |
| 25693082 | Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation. | Polish Journal of Pathology | 2014 |
| 25268370 | Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. | British Journal of Cancer | 2014 |
| 26165039 | [Breast cancer--selected aspects of systemic treatment]. | Polish Journal of Pathology | 2014 |
| 23246022 | Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. | Lancet Oncology, The | 2013 |
| 23814044 | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. | Oncologist | 2013 |
| 24192331 | Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. | Breast Cancer Research | 2013 |
| 23932548 | Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. | Lancet Oncology, The | 2013 |
| 23312888 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. | Lancet Oncology, The | 2013 |
| 23219286 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. | Lancet | 2013 |
| 23292831 | Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. | Medical Oncology | 2013 |
| 22153890 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. | Lancet Oncology, The | 2012 |
| 22504044 | Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. | Clin Cancer Res | 2012 |
| 22884505 | Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. | Lancet Oncology, The | 2012 |
| 22871798 | Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. | Oncologist | 2012 |
| 22149875 | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. | New England Journal of Medicine | 2012 |
| 21594854 | [Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardi | Kardiologia Polska | 2011 |
| 21429799 | Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. | Lancet Oncology, The | 2011 |
| 21115860 | Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. | J Clin Oncol | 2011 |
| 21189395 | Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. | J Clin Oncol | 2011 |
| 21321298 | Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. | Journal of Clinical Oncology | 2011 |
| 20819780 | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. | Ann Oncol | 2011 |
| 21853542 | Cancer epidemiology in Central, South and Eastern European countries. | Croatian Medical Journal | 2011 |
| 21911726 | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. | J Clin Oncol | 2011 |
| 21991949 | Adjuvant trastuzumab in HER2-positive breast cancer. | N Engl J Med | 2011 |
| 20578967 | Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer. | Clinical Chemistry and Laboratory Medicine | 2010 |
| 19669644 | Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. | Cancer Chemotherapy and Pharmacology | 2010 |
| 19717536 | Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. | Annals of Oncology | 2010 |